From the Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.
Pediatr Infect Dis J. 2024 Mar 1;43(3):242-249. doi: 10.1097/INF.0000000000004225. Epub 2023 Dec 25.
In June 2022, the mRNA COVID-19 vaccination was recommended for young children. We examined clinical characteristics and factors associated with vaccination status among vaccine-eligible young children hospitalized for acute COVID-19.
We enrolled inpatients 8 months to <5 years of age with acute community-acquired COVID-19 across 28 US pediatric hospitals from September 20, 2022 to May 31, 2023. We assessed demographic and clinical factors, including the highest level of respiratory support, and vaccination status defined as unvaccinated, incomplete, or complete primary series [at least 2 (Moderna) or 3 (Pfizer-BioNTech) mRNA vaccine doses ≥14 days before hospitalization].
Among 597 children, 174 (29.1%) patients were admitted to the intensive care unit and 75 (12.6%) had a life-threatening illness, including 51 (8.5%) requiring invasive mechanical ventilation. Children with underlying respiratory and neurologic/neuromuscular conditions more frequently received higher respiratory support. Only 4.5% of children hospitalized for COVID-19 (n = 27) had completed their primary COVID-19 vaccination series and 7.0% (n = 42) of children initiated but did not complete their primary series. Among 528 unvaccinated children, nearly half (n = 251) were previously healthy, 3 of them required extracorporeal membrane oxygenation for acute COVID-19 and 1 died.
Most young children hospitalized for acute COVID-19, including most children admitted to the intensive care unit and with life-threatening illness, had not initiated COVID-19 vaccination despite being eligible. Nearly half of these children had no underlying conditions. Of the small percentage of children who initiated a COVID-19 primary series, most had not completed it before hospitalization.
2022 年 6 月,mRNA COVID-19 疫苗被推荐用于幼儿。我们研究了有资格接种疫苗的因急性 COVID-19 住院的幼儿的临床特征和与疫苗接种状况相关的因素。
我们纳入了 2022 年 9 月 20 日至 2023 年 5 月 31 日期间在美国 28 家儿科医院因急性社区获得性 COVID-19 住院的 8 个月至<5 岁的住院患者。我们评估了人口统计学和临床特征,包括最高水平的呼吸支持,以及疫苗接种状况,定义为未接种、未完成或完成初级系列[至少接种 2(Moderna)或 3(辉瑞-生物技术)mRNA 疫苗剂量,在住院前≥14 天]。
在 597 名儿童中,174 名(29.1%)患者入住重症监护病房,75 名(12.6%)患有危及生命的疾病,包括 51 名(8.5%)需要有创机械通气。有呼吸和神经/神经肌肉疾病的儿童更频繁地接受更高水平的呼吸支持。仅 4.5%(n=27)因 COVID-19 住院的儿童完成了他们的 COVID-19 初级疫苗接种系列,7.0%(n=42)的儿童开始但未完成他们的初级系列。在 528 名未接种疫苗的儿童中,近一半(n=251)之前健康,其中 3 名因急性 COVID-19 需要体外膜氧合,1 名死亡。
尽管有资格接种疫苗,但大多数因急性 COVID-19 住院的幼儿,包括大多数入住重症监护病房和患有危及生命疾病的儿童,尚未开始 COVID-19 疫苗接种。这些儿童中有近一半没有基础疾病。在开始 COVID-19 初级系列的少数儿童中,大多数在住院前尚未完成。